1.5-T magnetic resonance-guided transgluteal biopsies of the prostate in patients with clinically suspected prostate cancer: Technique and feasibility

Investigative Radiology

Volumn 48, Issue 6, 2013, Pages 458-463

  Bodelle, Boris ^a   Naguib, Nagy N ^a,b   Schulz, Boris ^a   Eichler, Katrin ^a   Müller, Cindy ^a   Hansmann, Martin Leo ^a   Hammerstingl, Renate ^a   Hübner, Frank ^a   Vogl, Thomas J ^a   Zangos, Stephan ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Alexandria University   (Egypt)

Author keywords

core biopsy; interventional radiology; pelvic MRI; prostate; reproductive system

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY NEEDLE; CHRONIC PROSTATITIS; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEASIBILITY STUDY; FOLLOW UP; HEMATURIA; HEMOSPERMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; INFECTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; STEADY STATE;

EID: 84877576548     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31827c394b     Document Type: Article

References (35)

1. Beyersdorff D, Taupitz M, Winkelmann B, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology. 2002; 224:701-706.
2. Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasoundguided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997;50:562-566.
3. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1679-1684.
4. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166: 1679-1683.
5. Roehl KA, Antenor JAV, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435-2439.
6. Amsellem-Ouazana D, Younes P, Conquy S, et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol. 2005;47:582-586.
7. Zangos S, Eichler K, Engelmann K, et al. MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results. Eur Radiol. 2005;15:174-182.
8. Zangos S, Herzog C, Eichler K, et al. MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland. Eur Radiol. 2007;17:1118-1124.
9. Engelhard K, Hollenbach HP, Kiefer B, et al. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol. 2006;16:1237-1243.
10. Beyersdorff D, Winkel A, Hamm B, et al. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology. 2005;234:576-581.
11. Hata N, Jinzaki M, Kacher D, et al. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology. 2001;220:263-268.
12. Hambrock T, Futterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonanceYguided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol. 2008;43:686-694.
13. Yakar D, Heijmink SWTPJ, Hulsbergen-van de Kaa CA, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Invest Radiol. 2011;46:301-306
14. Scheenen TWJ, Futterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol. 2011;46:25-33.
15. Selns KM, Heerschap A, Jensen LR, et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol. 2012;47:624-633.
16. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score e 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47:153-158.
17. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-757.
18. Pondman K, Futterer JJ, ten Haken B, et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol. 2008; 54:517-527.
19. Hoeks CMA, Schouten MG, Bomers JGR, et al. Three-Tesla magnetic resonanceYguided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012; 62:902-909.
20. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183:520-527.
21. Yakar D, Hambrock T, Hoeks C, et al. Magnetic resonanceYguided biopsy of the prostate: feasibility, technique, and clinical applications. Top Magn Reson Imaging. 2008;19:291-295.
22. Yakar D, Schouten MG, Bosboom DGH, et al. Feasibility of a pneumatically actuated MR-compatible robot for transrectal prostate biopsy guidance. Radiology. 2011;260:241-247.
23. Schouten MG, Bomers JGR, Yakar D, et al. Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies. Eur Radiol. 2012; 22:476-483.
24. Papanicolaou N, Eisenberg PJ, Silverman SG, et al. Prostatic biopsy after proctocolectomy: a transgluteal, CT-guided approach. AJR Am J Roentgenol. 1996;166:1332-1334.
25. Zangos S, Melzer A, Eichler K, et al. MR-compatible assistance system for biopsy in a high-field-strength system: initial results in patients with suspicious prostate lesions. Radiology. 2011;259:903-910.
26. Gupta S, Nguyen HL, Morello FA, et al. Various approaches for CT-guided percutaneous biopsy of deep pelvic lesions: anatomic and technical considerations. Radiographics. 2004;24:175-189.
27. Susil RC, Menard C, Krieger A, et al. Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. J Urol. 2006;175:113-120.
28. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol. 2012;61:177-184.
29. Rodr?guez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol. 1998;160(6 pt 1):2115-2120.
30. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994;151: 1571-1574.
31. Yakar D, Hambrock T, Huisman H, et al. Feasibility of 3T dynamic contrastenhanced magnetic resonanceYguided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol. 2010; 45:121-125.
32. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011;186:1281-1285.
33. Shigemura K, Motoyama S, Yamashita M. Do additional cores from MRI cancer-suspicious lesions to systematic 12-core transrectal prostate biopsy give better cancer detection?. Urol Int. 2012;88:145-149.
34. de Oliveira A, Rauschenberg J, Beyersdorff D, et al. Automatic passive tracking of an endorectal prostate biopsy device using phase-only cross-correlation. Magn Reson Med. 2008;59:1043-1050.
35. Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative findingVmultiparametric MR imaging for detection and biopsy planning. Radiology. 2011;259:162-172.